Expression of Aurora-B and FOXM1 Predict Poor Survival in Patients with Nasopharyngeal Carcinoma

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2015 May 20

PMID 25986250

Citations 14

Authors

Pei-Yu Huang

Yan Li

Dong-Hua Luo

Xue Hou

Ting-Ting Zeng

Meng-Qing Li

Hai-Qiang Mai

Li Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this work was to investigate the relationship between Aurora-B, FOXM1, and clinical outcomes in patients with nasopharyngeal carcinoma (NPC) who were treated with a combination of induction chemotherapy and radiotherapy.

Patients And Methods: The expression of Aurora-B and FOXM1 were investigated by immunohistochemistry using a tissue microarray (TMA) containing samples from 166 NPC patients who were treated with cisplatin (DDP) + fluorouracil (5-FU) induction chemotherapy and radiotherapy between 1999 and 2005. The relationship of Aurora-B, FOXM1, and survival of these NPC patients was analyzed.

Results: Informative TMA results were obtained in 91 tumor cases for Aurora-B and 93 tumor cases for FOXM1. The 8-year failure-free survival rate (FFS) for the Aurora-B-negative and Aurora-B-positive group was 65.6 and 37.3%, respectively (p = 0.024), and the 8-year distant FFS (D-FFS) rate was 65.6 and 41.5%, respectively (p = 0.047). The 8-year overall survival (OS) in the FOXM1-negative group was moderately higher than in the FOXM1-positive group (58.4 vs 39.1%, p = 0.081). Cox regression analysis revealed that for FFS, Aurora-B expression was a significant prognostic factor (p = 0.025), while for D-FFS, Aurora-B expression was a marginally significant prognostic factor (p = 0.056). When FOXM1 expression was analyzed, the Cox regression analyses showed that FOXM1 expression was a marginally significant prognostic factor (p = 0.056) for OS. Correlation analysis showed that Aurora-B and FOXM1 expression had no significant correlation.

Conclusion: Aurora-B and FOXM1 were both adverse prognostic markers for NPC patients treated with chemoradiotherapy. However, the two markers had no significant correlation.

Citing Articles

GTSE1 promotes nasopharyngeal carcinoma proliferation and angiogenesis by upregulating STMN1.

Dong J, Chen J, Wu Y, Yan J Cell Div. 2024; 19(1):16.

PMID: 38698443 PMC: 11064356. DOI: 10.1186/s13008-024-00119-9.

Forkhead Box Protein M1 Promotes Nasopharyngeal Carcinoma Cell Tumorigenesis Possibly via the Wnt/β-Catenin Signaling Pathway.

Yu C, Chen H, Zhao Y, Zhang Y Med Sci Monit. 2021; 27:e931970.

PMID: 34911926 PMC: 8690047. DOI: 10.12659/MSM.931970.

"Metalloestrogenic" effects of cadmium downstream of G protein-coupled estrogen receptor and mitogen-activated protein kinase pathways in human uterine fibroid cells.

Yu L, Liu J, Yan Y, Burwell A, Castro L, Shi M Arch Toxicol. 2021; 95(6):1995-2006.

PMID: 33818655 PMC: 8166678. DOI: 10.1007/s00204-021-03033-z.

Aurora-B knockdown inhibits osteosarcoma metastasis by inducing autophagy via the mTOR/ULK1 pathway.

Wu X, Liu J, Song H, Yang Q, Ying H, Tong W Cancer Cell Int. 2020; 20(1):575.

PMID: 33292257 PMC: 7706191. DOI: 10.1186/s12935-020-01674-1.

[Aurora kinase-B silencing promotes apoptosis of osteosarcoma 143B cells by ULK1 phosphorylation-induced autophagy].

Wu X, Liu J, Song H, Yang Q, Ying H, Liu Z Nan Fang Yi Ke Da Xue Xue Bao. 2020; 40(9):1273-1279.

PMID: 32990233 PMC: 7544570. DOI: 10.12122/j.issn.1673-4254.2020.09.08.

References

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y . AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110(6):2034-40. DOI: 10.1182/blood-2007-02-073700. View

Mortlock A, Foote K, Heron N, Jung F, Pasquet G, Lohmann J . Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 2007; 50(9):2213-24. DOI: 10.1021/jm061335f. View

Lee A, Sze W, Au J, Leung S, Leung T, Chua D . Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61(4):1107-16. DOI: 10.1016/j.ijrobp.2004.07.702. View

Razak A, Siu L, Liu F, Ito E, OSullivan B, Chan K . Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010; 46(11):1967-78. DOI: 10.1016/j.ejca.2010.04.004. View

Tovuu L, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Arakawa Y . The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma. Int J Clin Oncol. 2013; 19(4):622-8. DOI: 10.1007/s10147-013-0593-y. View

Chen H, Yang C, Yu L, Xie L, Hu J, Zeng L . Adenovirus-mediated RNA interference targeting FOXM1 transcription factor suppresses cell proliferation and tumor growth of nasopharyngeal carcinoma. J Gene Med. 2012; 14(4):231-40. DOI: 10.1002/jgm.2614. View

Mehra R, Serebriiskii I, Burtness B, Astsaturov I, Golemis E . Aurora kinases in head and neck cancer. Lancet Oncol. 2013; 14(10):e425-35. PMC: 4139969. DOI: 10.1016/S1470-2045(13)70128-1. View

Chen Y, Chen C, Twu N, Yen M, Lai C, Wu H . Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch. 2009; 455(5):431-40. DOI: 10.1007/s00428-009-0838-3. View

Wang Y, Wu M, Sham J, Zhang W, Wu W, Guan X . Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002; 95(11):2346-52. DOI: 10.1002/cncr.10963. View

10.

Jiang L, Wang P, Chen H . Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma. Ups J Med Sci. 2014; 119(4):324-32. PMC: 4248072. DOI: 10.3109/03009734.2014.960053. View

11.

Erpolat O, Gocun P, Akmansu M, Karakus E, Akyol G . High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Strahlenther Onkol. 2012; 188(3):248-54. DOI: 10.1007/s00066-011-0042-7. View

12.

Carmena M, Earnshaw W . The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003; 4(11):842-54. DOI: 10.1038/nrm1245. View

13.

Yeh S, Tang Y, Lui C, Huang Y, Huang E . Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2005; 62(3):672-9. DOI: 10.1016/j.ijrobp.2004.11.002. View

14.

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour J . Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 2012; 287(35):29887-98. PMC: 3436153. DOI: 10.1074/jbc.M112.371682. View

15.

Yasen M, Mizushima H, Mogushi K, Obulhasim G, Miyaguchi K, Inoue K . Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci. 2009; 100(3):472-80. PMC: 11158790. DOI: 10.1111/j.1349-7006.2008.01068.x. View

16.

Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena B, Shimamoto F . Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch. 2007; 450(3):297-302. DOI: 10.1007/s00428-006-0360-9. View

17.

Dees E, Cohen R, von Mehren M, Stinchcombe T, Liu H, Venkatakrishnan K . Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res. 2012; 18(17):4775-84. DOI: 10.1158/1078-0432.CCR-12-0589. View

18.

Takeshita M, Koga T, Takayama K, Ijichi K, Yano T, Maehara Y . Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer. 2013; 80(1):85-90. DOI: 10.1016/j.lungcan.2012.12.018. View

19.

Baujat B, Audry H, Bourhis J, Chan A, Onat H, Chua D . Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2005; 64(1):47-56. DOI: 10.1016/j.ijrobp.2005.06.037. View

20.

Lee N, Xia P, Quivey J, Sultanem K, Poon I, Akazawa C . Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53(1):12-22. DOI: 10.1016/s0360-3016(02)02724-4. View